<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the correlation between plasma ratio of dihydrouracil/<z:chebi fb="0" ids="17568">uracil</z:chebi> (UH2/<z:chebi fb="0" ids="17568">Ura</z:chebi>), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) treatment efficacy in rats with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>5-FU pharmacokinetic and pharmacodynamic studies were performed using DPD circadian variation in rats with 1,2-dimethylhydrazine-induced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>By plotting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume after 5-FU treatment against pre-therapeutic plasma UH2/<z:chebi fb="0" ids="17568">Ura</z:chebi>, we inferred a linear relationship (r(2) = 0.988) </plain></SENT>
<SENT sid="3" pm="."><plain>5-FU concentration fluctuations induced by DPD activity variation affected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients receiving proper dosing regimens, plasma UH2/<z:chebi fb="0" ids="17568">Ura</z:chebi> could be an indirect biomarker for predicting 5-FU treatment efficacy, <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, and 5-FU doses </plain></SENT>
</text></document>